203 related articles for article (PubMed ID: 35524024)
1. Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis.
Mori Y; Harada T; Yoshimoto G; Shima T; Numata A; Jinnouchi F; Yamauchi T; Kikushige Y; Kunisaki Y; Kato K; Takenaka K; Akashi K; Miyamoto T
Int J Hematol; 2022 Aug; 116(2):258-265. PubMed ID: 35524024
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection.
Takenaka K; Fuji S; Matsukawa T; Uchida N; Kobayashi T; Tanaka M; Ara T; Ikegame K; Ozawa Y; Kanda Y; Sawa M; Maruyama Y; Fukuda T; Nakamae H; Kimura T; Ogata M; Seo S; Atsuta Y; Matsuo K; Nakasone H
Ann Hematol; 2024 Jan; 103(1):285-296. PubMed ID: 37947825
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data.
Mori Y; Jinnouchi F; Takenaka K; Aoki T; Kuriyama T; Kadowaki M; Odawara J; Ueno T; Kohno K; Harada T; Yoshimoto G; Takase K; Henzan H; Kato K; Ito Y; Kamimura T; Ohno Y; Ogawa R; Eto T; Nagafuji K; Akashi K; Miyamoto T
Bone Marrow Transplant; 2021 Apr; 56(4):853-862. PubMed ID: 33139867
[TBL] [Abstract][Full Text] [Related]
4. Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis.
Włodarczyk M; Wieczorkiewicz-Kabut A; Białas K; Koclęga A; Noster I; Zielińska P; Helbig G
Turk J Haematol; 2024 Mar; 41(1):9-15. PubMed ID: 38345092
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus Immune reconstitution in cord blood transplant recipients on letermovir prophylaxis.
Abidi MZ; Molina KC; Garth K; Gutman JA; Weinberg A
Transpl Infect Dis; 2023 Oct; 25(5):e14104. PubMed ID: 37436771
[TBL] [Abstract][Full Text] [Related]
6. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
[TBL] [Abstract][Full Text] [Related]
7. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
Jung S; Michel M; Stamminger T; Michel D
BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
[TBL] [Abstract][Full Text] [Related]
8. Letermovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation.
Richert-Przygonska M; Jaremek K; Debski R; Konieczek J; Lecka M; Dziedzic M; Bogiel T; Styczynski J; Czyzewski K
Anticancer Res; 2022 Jul; 42(7):3607-3612. PubMed ID: 35790275
[TBL] [Abstract][Full Text] [Related]
9. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
[TBL] [Abstract][Full Text] [Related]
10. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
Liu LW; Yn A; Gao F; Olson M; Crain M; Abboud R; Westervelt P; Abboud C; Vij R; Stockerl-Goldstein K; Pusic I; Cashen AF; Schroeder MA
Transplant Cell Ther; 2022 Aug; 28(8):510.e1-510.e9. PubMed ID: 35598841
[TBL] [Abstract][Full Text] [Related]
11. Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study.
Brusosa M; Ruiz S; Monge I; Solano MT; Rosiñol L; Esteve J; Carreras E; Marcos MÁ; Riu G; Carcelero E; Martinez C; Fernández-Avilés F; Rovira M; Suárez-Lledó M; Salas MQ
Ann Hematol; 2024 Feb; 103(2):609-621. PubMed ID: 37957371
[TBL] [Abstract][Full Text] [Related]
12. Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data.
Pang I; Chen P; Trinh GV; Remberger M; Novitzky-Basso I; Gerbitz A; Kim DD; Kumar R; Lam W; Law AD; Lipton JH; Viswabandya A; Pasic I; Mattsson J; Michelis FV
Eur J Haematol; 2024 Feb; 112(2):301-309. PubMed ID: 37830403
[TBL] [Abstract][Full Text] [Related]
13. Extended duration letermovir in allogeneic hematopoietic stem cell transplant.
Hinman B; Cox J; Umoru G; Kamble R; Musick W
Transpl Immunol; 2023 Dec; 81():101936. PubMed ID: 37770000
[TBL] [Abstract][Full Text] [Related]
14. Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP).
Galaverna F; Baccelli F; Zama D; Tridello G; Masetti R; Soncini E; Mura R; Barzaghi F; Colombini A; Prunotto G; D'Amico MR; Calore E; Biffi A; Perruccio K; Gasperini P; Oltolini C; Quagliarella F; Giacomazzi A; Pagliara D; Locatelli F; Cesaro S
Bone Marrow Transplant; 2024 Apr; 59(4):505-512. PubMed ID: 38272999
[TBL] [Abstract][Full Text] [Related]
15. Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Lin A; Flynn J; DeRespiris L; Figgins B; Griffin M; Lau C; Proli A; Devlin SM; Cho C; Tamari R; Jakubowski AA; Papadopoulos EB; Giralt SA; Perales MA; Seo SK; Shaffer B
Transplant Cell Ther; 2021 Jan; 27(1):85.e1-85.e6. PubMed ID: 33053449
[TBL] [Abstract][Full Text] [Related]
16. Human herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis.
Kampouri E; Zamora D; Kiem ES; Liu W; Ibrahimi S; Blazevic RL; Lovas EA; Kimball LE; Huang ML; Jerome KR; Ueda Oshima M; Mielcarek M; Zerr DM; Boeckh MJ; Krantz EM; Hill JA
Clin Microbiol Infect; 2023 Nov; 29(11):1450.e1-1450.e7. PubMed ID: 37532126
[TBL] [Abstract][Full Text] [Related]
17. Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients.
Royston L; Royston E; Masouridi-Levrat S; Chalandon Y; Van Delden C; Neofytos D
Immun Inflamm Dis; 2021 Sep; 9(3):771-776. PubMed ID: 33949798
[TBL] [Abstract][Full Text] [Related]
18. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
Sassine J; Khawaja F; Shigle TL; Handy V; Foolad F; Aitken SL; Jiang Y; Champlin R; Shpall E; Rezvani K; Ariza-Heredia EJ; Chemaly RF
Clin Infect Dis; 2021 Oct; 73(8):1346-1354. PubMed ID: 33830182
[TBL] [Abstract][Full Text] [Related]
19. Immunovirology of cytomegalovirus infection in allogeneic stem cell transplant recipients undergoing prophylaxis with letermovir: A narrative review.
Solano C; Giménez E; Albert E; Piñana JL; Navarro D
J Med Virol; 2023 Aug; 95(8):e29005. PubMed ID: 37526411
[TBL] [Abstract][Full Text] [Related]
20. Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program.
Robin C; Thiebaut A; Alain S; Sicre de Fontbrune F; Berceanu A; D'Aveni M; Ceballos P; Redjoul R; Nguyen-Quoc S; Bénard N; Pahlavan-Grumel G; Cordonnier C
Biol Blood Marrow Transplant; 2020 May; 26(5):978-984. PubMed ID: 32035273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
